CENTRAL MEDICAL SERVICES SOCIETY

Ministry of Health & Family Welfare (Autonomous Body under MoHFW, Govt. of India) 2nd Floor, Vishwa Yuvak Kendra, Pandit Uma Shankar Dikshit Road, Chanakyapuri, New Delhi-110021 PHONE -:011-21410905/6, Fax -:011-21410849

Date: - 07.07.2023

Minutes of Pre-bid Meeting For Procurement of TABLET RIFAPENTINE 300MG+ ISONIAZID 300MG for NTEP CPP Tender ID: 2023_CMSS_759825_1, dated 29.06.2023 Pre-bid Meeting held on 04.07.2023 at 11:30 AM

- 1. Following officials were present during the Pre-bid meeting: -
 - (i) Dr. Alok Mathur, Addl. DDG (NTEP)
 - (ii) Mr. D Mohapatra, GM (Finance), CMSS
 - (iii) Ms. Anjana, GM (Procurement), CMSS
 - (iv) Mr. Lava Mishra, AGM (Procurement), CMSS
 - (v) Ms. Akanksha Jain, AGM (QA), CMSS
- 2. Following representatives from prospective bidders were present during the Pre-bid meeting: -

| Sr. No. | Name of Representative | Name of firm |
|---------|------------------------|-----------------------------------|
| 1 | Mr. Harish Joshi | M/s Macleod Pharma Ltd. |
| 2 | Mr. Pawan Chopra | M/s Bharat Parenterals |
| 3 | Mr. Atul Yadav | M/s Lupin Ltd. |
| 4 | Mr. Alok Kumar | M/s J Duncan Healthcare Pvt. Ltd. |

3. Queries from following prospective firms were received via email: -

| Sr. No. | Name of the bidders | | | |
|---------|---------------------|-----------------------------------|--|--|
| 1 | M/s. OXALIS LABS | M/s J Duncan Healthcare Pvt. Ltd. | | |

4. Points raised by representatives of prospective bidders were discussed. After due consideration of the queries, the remarks are enclosed.

TABLE-APre-bid queries raised by the prospective bidders & remarks by CMSS

| Sr. No. | As per tender | Tender clause no. | Bidder's Representation | Bidder's Name | Response |
|------------|--|--|---|--|---|
| 1. | Tender timelines are as under: (d) Last date and time for bid submission: - 13/07/2023 at 3:00 PM | Critical Date Sheet | We request you to extend the deadline to submit the bid, the time given is less also we need time to get the documents from FDA, Bank and Chartered Accountant Documents which takes time to get and also as the tender format is changes, we need to work on all the documents again Kindly extend the Bid submission end date is 30/07/2023 at 3.00PM Reasons: - we had applied for approval of new product in form CT 23 to CDSCO, after approval from CDSCO, 7 working days required for obtaining the manufacturing License for domestic from SLA (State Licensing Authority). we are still waiting for approval from | M/s. OXALIS LABS M/s J Duncan Healthcare Pvt. Ltd. | No changes. |
| 2. | For SCH. I TRANCHE I- 50% of the total quantity to be delivered within 90 days from the date of issue of LOA. TRANCHE II-25% of the total quantity to be delivered within 180-210 days from the date of issue of LOA. TRANCHE III-25 % of the total quantity to be delivered within 270-300 days from the date of issue of LOA. | Annexure I & IA - List of Product & Their Technical Specifica tions | CDSCO. And as on receipt of the LOA or PO, for the supply of drugs to CMSS, the supply period for Tranche I quantity as per the tender clause was 60 days from the date of issue of LOA which is likely not possible as because as below: - It takes minimum 30 to 60 days to complete with production dependency. After production, it takes a further 10 to 15 days to receive COA. After the products have been inspected by you, it takes additional 20-30 days to receive the inspection reports. | M/s. OXALIS LABS | Amended as: - TRANCHE I- 35% of the total quantity to be delivered within 90 days from the date of issue of LOA. TRANCHE II- 35% of the total quantity to be delivered within 180- 210 days from the date of issue of LOA. TRANCHE III- 30% of the total quantity to be delivered within 270-300 days from the date of issue of LOA. |

| Its takes at least 30 days for | | |
|--|------------|--|
| the goods to be delivered to | | |
| all location, thus making | | |
| the delivery possible in | | |
| roughly 100 to 130 days. | | |
| 100 to 100 days. | | |
| In light of the fact that it | | |
| will actually be unable to | | |
| get first tranche dispatched | | |
| in 60 days, we hereby | | |
| request you to kindly | | |
| consider or give us a | | |
| minimum of days rather | | |
| than 120 days in order to | | |
| seamless delivery without | | |
| any LD Charges. | | |
| Also, after goods readiness | | |
| it takes time for Inspection | | |
| Report for approx. 30 days | | |
| thus | | |
| increase the Lead time OR | | |
| allow us to ship the goods | | |
| parallel to inspection. OR if | | |
| Tranche-1 (50%) is been | | |
| converted in 2 lot i.e. 20:30 | | |
| then we shall request you to | | |
| consider 20% to be | | |
| supplied in 90 days & | | |
| balance 30% within 120 | | |
| days. Kindly confirm. | | |
| Annexure I- Delivery | M/s J | |
| Schedule | Duncan | |
| For SCH J | Healthcare | |
| For SCH. I | Pvt. Ltd. | |
| TRANCHE I- 20% of the | | |
| total quantity to be | | |
| delivered within 60 days from the date of issue of | | |
| LOA. | | |
| TRANCHE II- 30% of the | | |
| total quantity to be | | |
| delivered within 61-120 | | |
| days from the date of issue | | |
| of LOA. | | |
| TRANCHE III-25% of | | |
| the total quantity to be | | |
| delivered within 180-210 | | |
| days from the date of issue | | |
| of LOA. | | |
| TRANCHE IV-25% of | | |
| the total quantity to be | | |
| delivered within 270-300 | | |
| days from the date of issue | | |
| of LOA. | | |
| | | |
| OR | | |

| | | | TRANCHE I- 25% of the | | |
|-----|-----------------------------|-----------|---|------------|---------------------|
| | | | total quantity to be | | |
| | | | delivered within 90 days | | |
| | | | from the date of issue of | | |
| | | | LOA. | | |
| | | | TRANCHE II- 25% of the | | |
| | | | total quantity to be | | |
| | | | delivered within 91-180 | | |
| | | | days from the date of issue | | |
| | | | of LOA. | | |
| | | | TRANCHE III- 25 % of | | |
| | | | the total quantity to be | | |
| | | | delivered within 181-270 | | |
| | | | days from the date of issue | | |
| | | | of LOA. | | |
| | | | TRANCHE IV- 25 % of | | |
| | | | | | |
| | | | the total quantity to be delivered within 271-360 | | |
| | | | | | |
| | | | days from the date of issue | | |
| | | | of LOA. | | |
| | | | Reasons: - Huge Qty. and | | |
| | | | new drug in India time & | | |
| | | | supply of API. | | CD C 111 1 |
| 3. | 3) Refer to Inspection | Annexure | Refer to this clause we | M/s. | CRC will not be |
| | Methodology (PDI/NON | I & IA - | hereby request you to | OXALIS | applicable for this |
| | PDI) - | List of | 2 | LABS | tender. |
| | Non-PDI (Inspection at | Product | do not have to submit the | | |
| | Delivery Stages) | & Their | CRC copy along with the | | |
| | | Technical | post shipment documents | | |
| | | Specifica | as it is NON PDI. Please | | |
| | | tions | confirm | | 27.1 |
| 4. | Refer to Point pt # | 18.2 | Refer to this clause, we | M/s. | No changes. |
| | 18(18.2) — Delays in | | hereby request you to | OXALIS | |
| | Suppliers Performance | | kindly remove this | LABS | |
| | (page #33): - If the supply | | clause or to reduce the | | |
| | reaches the designated | | percentage of penalty per | | |
| | consignee places or | | week | | |
| | CMSS Warehouse after | | Liquidated damages | M/s J | |
| | scheduled delivery• date | | If the supply reaches the | Duncan | |
| | mentioned in LOA/P.O, | | designated consignee | Healthcare | |
| | liquidated damages will | | places or CMSS | Pvt. Ltd. | |
| | be levied @ 2.5% per | | Warehouse after scheduled | | |
| | week to be applied | | delivery date mentioned in | | |
| | proportionately on per | | LOA/P.O, liquidated | | |
| | day basis up to a | | damages will be levied | | |
| | maximum of 10% of | | @ 0.5% per week to be | | |
| | P.O. Cost, irrespective | | applied proportionately on | | |
| | of the fact that | | per day basis up to a | | |
| | whether the CMSS has | | maximum of 10% of un- | | |
| | suffered any | | supplied | | |
| | damage/loss or not, on | | goods, irrespective of the | | |
| | account of delay in | | fact that whether the CMSS | | |
| | effecting supply. If the | | has suffered any damage/ | | |
| | last schedule delivery | | loss or not, on account of | | |
| | day happens to be a | | delay in effecting supply. If | | |
| | holiday the supply will be | | the last scheduled delivery | | |
| 1 1 | J | | | 1 | |

| | accepted on the next | | day happens to be a holiday | | |
|----|---|-------|--|--------|----------------------|
| | working day without any | | the supply will be accepted | | |
| | penalty. | | on the next working day | | |
| | 1 2 | | without any penalty. | | |
| | | | Deserves | | |
| | | | Reasons:- As per provision of GFR and | | |
| | | | Manual of Procurement | | |
| | | | and Guidelines of MoF | | |
| | | | (DoE). | | |
| 5. | Miscellaneous | | This is just to confirm from | M/s. | All format and terms |
| | | | you that can we can use last | OXALIS | & conditions will be |
| | | | tender format Tender No. | LABS | applicable according |
| | | | CMSS/PROC/2023- | | to tender ref no. |
| | | | 24/NTEP/008 Dated | | CMSS/PROC/2023- |
| | | | 01.05.2023. Please confirm | | 24/NTEP/026. |
| 6. | (i) Long Term (Real | 6 (n) | the same. | M/s. | No changes |
| 0. | Time) Stability Data of | 6 (n) | Refer to this clause, we hereby request you to | OXALIS | No changes. |
| | the quoted product in | | consider Long Term (Real | LABS | |
| | specified packing for at | | Term) & Accelerated Term | Lindo | |
| | least for 3 batches, to | | Stability Shelf Life to | | |
| | support shelf life. | | consider as Mandatory. | | |
| | However, For the | | | | |
| | drugs recently introduced | | | | |
| | drugs in the county | | | | |
| | (introduced in the last | | | | |
| | two years), the | | | | |
| | requirement for Long Term (Real Time) | | | | |
| | Stability Data of the | | | | |
| | quoted product in | | | | |
| | specified packing for at | | | | |
| | least for 3 batches, to | | | | |
| | support shelf life shall be | | | | |
| | waived off. Point no (iii) | | | | |
| | shall be applicable. | | | | |
| | (II) Only for the drugs | | | | |
| | introduced in Indian | | | | |
| | Pharmacopoeia in the recent past (last 2yrs), | | | | |
| | Long Term (Real Time) | | | | |
| | Stability Data for | | | | |
| | previously approved | | | | |
| | Pharmacopoeia r in- | | | | |
| | house Standards shall | | | | |
| | be accepted, as the case | | | | |
| | may be. | | | | |
| | (iii) Accelerated Stability | | | | |
| | data for a period of 6 months in specified | | | | |
| | months in specified packing for at least 3 | | | | |
| | batches and available | | | | |
| | Lung term (Real Time) | | | | |
| | stability data as | | | | |
| | available for the | | | | |
| L | 101 110 | | l | I | 1 |

| | quoted product shall | | | | |
|----|------------------------------|---------|---------------------------------|------------|---------------------|
| | be submitted. | | | | |
| | (iv) Certificate of | | | | |
| | Analysis of one batch of | | | | |
| | the quoted product | | | | |
| | should be submitted. | | | | |
| 7. | Tenderer shall be a | 4 (c) & | Tenderer shall be a | M/s J | Amended As: - |
| | manufacturer of the | 6.2 (c) | manufacturer of the quoted | Duncan | |
| | quoted product and | | product and having valid | Healthcare | Tenderer shall be |
| | having valid own | | own manufacturing license | Pvt. Ltd. | a manufacturer of |
| | manufacturing license in | | in the indicate | I VI. Elu. | the quoted product |
| | the indicate | | pharmacopeia (in technical | | and having valid |
| | pharmacopeia (in | | specification at Annexure | | own |
| | | | IA) and Certificate of | | manufacturing |
| | technical specification at | | Pharmaceutical Product | | license in the |
| | Annexure IA) and | | | | |
| | Certificate of | | (COPP) as recommended | | indicate |
| | Pharmaceutical Product | | by WHO in any of the | | pharmacopeia (in |
| | (COPP) as recommended | | pharmacopeia | | technical |
| | by WHO in any of the | | IP/BP/USP/IHS (In House | | specification at |
| | pharmacopeia | | Standard). The | | Annexure IA) and |
| | IP/BP/USP. The | | manufacturing license & | | Certificate of |
| | manufacturing license & | | COPP should be valid on | | Pharmaceutical |
| | COPP should be valid on | | the date of tender opening | | Product (COPP) |
| | the date of tender | | packet 1. In case of failure | | as recommended |
| | opening packet 1. In case | | to submit the same, the bid | | by WHO in any of |
| | of failure to submit the | | shall not be considered any | | the pharmacopeia |
| | same, the bid shall not be | | further. | | IP/BP/USP/IHS |
| | considered any further. | | | | (In House |
| | | | The Tenderer should | | Standard). The |
| | The Tenderer should | | furnish the own domestic | | manufacturing |
| | furnish the domestic | | Manufacturing License in | | license & COPP |
| | Manufacturing License | | Form of 25 / 28 issued from | | should be valid on |
| | in Form of 25 / 28 issued | | State Licensing Authority | | the date of tender |
| | from State Licensing | | along with the approval of | | opening packet 1. |
| | Authority along with the | | DCGI in Form of 46/ CT- | | In case of failure |
| | approval of DCGI in | | 23 as new drug approved | | to submit the |
| | Form of 46/ CT-23 as | | by DCGI and IPC (Indian | | same, the bid shall |
| | new drug approved by | | Pharmacopeia | | not be considered |
| | DCGI. | | Commission) Test report. | | any further. |
| | | | | | |
| | For drugs that are not | | Reasons- Drugs newly | | The Tenderer |
| | available in IP, other | | introduced in India and | | should furnish the |
| | official Pharmacopeia (s) | | Programme Division | | domestic |
| | are applicable. If a drug is | | NTEP procured first time | | Manufacturing |
| | not available in any of the | | in India. To establish the | | License in Form |
| | official pharmacopeias, | | quality of the product | | of 25 / 28 issued |
| | 'In House' standards are | | above mentioned | | from State |
| | applicable as per the | | requirement are should | | Licensing |
| | Drugs and Cosmetics Act | | be mandatory. | | Authority along |
| | 1940 and the Rules | | | | with the approval |
| | therein. | | The Tenderer should | | of DCGI in Form |
| | | | furnish the API | | of 46/ CT-23 as |
| | Bidder is requested to | | Manufacturing License | | new drug |
| | submit an undertaking | | along with the approval | | approved by |
| | that the drug is not | | of DCGI as new drug | | DCGI. |
| | available in IP or any | | approved by DCGI and | | |
| | | | | | |

| | other approved | | IPC (Indian | | For drugs that are |
|----|----------------------------|-------------|---|------------|----------------------|
| | pharmacopeia. | | Pharmacopeia | | not available in IP, |
| | P | | Commission) Test report. | | other official |
| | | | To establish the quality | | Pharmacopeia (s) |
| | | | source of API. | | are applicable. If a |
| | | | source of All I. | | drug is not |
| | | | For drugs that are not | | available in any of |
| | | | available in IP, other | | the official |
| | | | official Pharmacopeia (s) | | pharmacopeias, |
| | | | are applicable. If a drug is | | 'In House' |
| | | | | | |
| | | | not available in any of the | | |
| | | | official pharmacopeias, 'In House' standards are | | applicable as per |
| | | | | | the Drugs and |
| | | | applicable as per the Drugs | | Cosmetics Act |
| | | | and Cosmetics Act 1940 | | 1940 and the |
| | | | and the Rules therein. | | Rules therein. |
| | | | Diddan is a contract to the | | Diddon ' |
| | | | Bidder is requested to | | Bidder is |
| | | | submit an undertaking that | | requested to |
| | | | the drug is not available in | | submit an |
| | | | IP or any other approved | | undertaking that |
| | | | pharmacopeia. | | the drug is not |
| | | | | | available in IP or |
| | | | Loan License should not | | any other |
| | | | be eligible to bid. | | approved |
| | | | | | pharmacopeia. |
| 8. | Tenderer should quote at | 4 (h) | Tenderer should quote at | M/s J | No changes. |
| | least for 50% of the | | least for 25% of the tender | Duncan | |
| | tender quantity of each | | quantity of each items | Healthcare | |
| | items quoted and the | | quoted and the tenderer | Pvt. Ltd. | |
| | tenderer shall have an | | shall have an annual | | |
| | annual production | | production capacity not | | |
| | capacity not less than one | | less than one and half times | | |
| | and half times the | | the quantity quoted for | | |
| | quantity quoted for each | | each schedule. | | |
| | schedule. | | | | |
| | | | Reasons: - API | | |
| | | | production is limited. | | |
| 9. | Tenderer should have | 4 (i) & 6.2 | Tenderer should have | M/s J | Amended as: - |
| | supplied 40% of the | (e) | supplied 40% of the quoted | Duncan | |
| | quoted quantity of same | | quantity of same or similar | Healthcare | Tenderer should |
| | or similar items during | | items during the last three | Pvt. Ltd. | have supplied |
| | the last two financial | | financial years. Bidder | | 40% of the quoted |
| | years. Bidder should | | should submit Purchase | | quantity of same |
| | submit Purchase order | | order copies and certificate | | or similar items |
| | copies and certificate | | duly issued by statutory | | during the last two |
| | duly issued by statutory | | auditor of the company on | | financial years. |
| | auditor of the company | | his letter head by certifying | | Bidder should |
| | on his letter head by | | the quantities | | submit Purchase |
| | certifying the quantities | | manufactured and | | order copies and |
| | manufactured and | | marketed in trade, export, | | certificate duly |
| | marketed in trade, export, | | open market, sold to | | issued by |
| | open market, sold to | | government institutions, | | Statutory |
| | government institutions, | | private bodies etc. and the | | Auditor/Practising |
| | private bodies etc. and | | marketed quantities are not | | Chartered |
| 1 | | | | | |
| | the marketed quantities | | | | Accountant of the |

| are not less than at least | less than at least 40% of the | company on his |
|----------------------------|----------------------------------|---------------------|
| 40% of the quoted/ | quoted/ similar items. | letter head by |
| similar items. | | certifying the |
| | Similar Items here relate to | quantities |
| Similar Items here relate | the following: - | manufactured and |
| to the following: - | Similar item means | marketed in trade, |
| Similar item means | quoted/any TB Drug | export, open |
| quoted/any TB Drug | | market, sold to |
| | Supply/Sale/Service order | government |
| Supply/Sale/Service | under loan license | institutions, |
| order under loan license | arrangement shall not be | private bodies etc. |
| arrangement shall not be | considered. | and the marketed |
| considered. | | quantities are not |
| | OR | less than at least |
| | | 40% of the |
| | Tenderer should have | quoted/ similar |
| | submit any three | items. |
| | Purchase order copies of | |
| | any Govt. entities/ | Similar Items |
| | Autonomous body for | here relate to the |
| | any quantity of Anti TB | following: - |
| | Drugs during the last two | Similar item |
| | financial years. Bidder | means quoted/any |
| | should submit Purchase | TB Drug |
| | order copies and certificate | 12 2108 |
| | duly issued by statutory | Supply/Sale/Serv |
| | auditor of the company on | ice order under |
| | his letter head by certifying | loan license |
| | the quantities | arrangement |
| | manufactured and | shall not be |
| | marketed to government | considered. |
| | institutions. | constact cu. |
| | institutions. | |
| | OR | |
| | Tenderer should have | |
| | supplied 40% of the quoted | |
| | quantity of same or similar | |
| | items during the last two | |
| | financial years. Bidder | |
| | should submit Purchase | |
| | | |
| | order copies and certificate | |
| | duly issued by statutory | |
| | auditor of the company on | |
| | his letter head by certifying | |
| | the quantities | |
| | manufactured and | |
| | marketed in trade, export, | |
| | open market, sold to | |
| | government institutions, | |
| | private bodies etc. and the | |
| | | |
| | marketed quantities are not | |
| | less than at least 40% of the | |
| | | |

| Similar Items here relate to the following: - Similar item means any Tablet (we have Manufacturing Lic, CoPP, MMC- Manufacturing and Marketing standing certificate, Capacity Certificate which is issued by Licensing Authority). | |
|---|--|
| We had supplied various tablets in CMSS, BPPI, Punjab Health Corp., RMSCL, UPMSCL, MPPHSC, Maharashtra Govt,, OMSCL, BMSCL etc | |
| Supply/Sale/Service order under loan license arrangement shall not be considered. OR | |
| Relaxation of Prior experience criteria for MSME and Startup entities as per Deptt. of Expenditure order no F.20/2/2014- PPD (pt.) dt. 20/09/2016. Copy enclosed. | |
| Stipulated tender conditions also amended in CMSS previous tender also. (ARV Tender No- 013 for 2023-24 for NACO, NACO HIV Kit Tender for 2022-23, NACO CD 4 Tender, DEC Tablet Tender for NVBDCP, First Line Anti TB Drugs etc. | |
| Stipulatedtenderconditionsrestrictiveparticipatethebidderandeliminateparticipation.Stipulatedtender | |

| | | | by Any other Govt. | | |
|-----|--|---------------------|--|--|-------------|
| | | | Procurement entities. | | |
| 10. | A valid Certificate of Pharmaceutical Product (COPP) as recommended by WHO in any pharmacopeia IP/BP/USP and a valid WHO-GMP. | 6 (i) | Requirement of Certificate of Pharmaceutical Product (COPP) as recommended by WHO in any pharmacopeia IP/BP/USP should be deleted. A valid WHO-GMP should be submitted. Reasons- Drugs recently | M/s J Duncan Healthcare Pvt. Ltd. | No changes. |
| | | | introduced in India 2021. | | |
| 11. | Duly notarized general power of Attorney (on non-judicial stamp paper of worth Rs. 50/-) in favour of authorized signatory in case of partnership firm (to be signed by all partners) / proprietorship firm or board resolution in case of a company to sign the bid and bind the bidder. The signature of authorized signatory should be duly attested. In case of proprietorship on its letter head of firm declares himself as proprietor with specimen signature. | 6 (d) | Duly notarized general power of Attorney (on non- judicial stamp paper of worth Rs. 50/- or more) in favour of authorized signatory in case of partnership firm (to be signed by all partners) / proprietorship firm or board resolution in case of a company to sign the bid and bind the bidder. The signature of authorized signatory should be duly attested. In case of proprietorship on its letter head of firm declares himself as proprietor with specimen signature. | M/s J Duncan Healthcare Pvt. Ltd. | Accepted. |
| 12. | Annexure-VIII NOTARISED UNDERTAKING BY MSE COMPANIES (In 20- Rupees stamp paper) | | Annexure-VIII NOTARISED UNDERTAKING BY MSE COMPANIES (In 20- Rupees or more rupees stamp paper) | M/s J Duncan Healthcare Pvt. Ltd. | Accepted. |
| 13. | Annexure III-EMD EMD For Sch. I- As per Annexure III. | Annexure III-EMD | Bid security declaration also allowed in compliance of GFR 2017 Rule no 170(iii). In place of a Bid security, the Ministries/ Departments may require Bidders to sign a Bid securing declaration accepting that if they withdraw or modify their Bids during the period of validity, or if they are awarded the contract and they fail to sign the | M/s J Duncan Healthcare Pvt. Ltd. | No changes. |

| | | | contract, or to submit a performance security before the deadline defined in the request for bids document, they will be suspended for the period of time specified in the request for bids document from being eligible to submit Bids for contracts with the entity that invited the Bids. Reasons: - Wider participation for small | | |
|-----|--|--|---|-------------------|---|
| 14. | Typo Error: Online short tender for procurement of Tablet Rifapentine 300 mg + Isoniazid 30 mg for NTEP | | entities. It should read as: Online short tender for procurement of Tablet Rifapentine 300 mg + Isoniazid 300 mg for NTEP. Kindly clarify | M/s Lupin Ltd. | Kindly read Tablet Rifapentine 300 mg + Isoniazid 300 mg in place of Tablet Rifapentine 300 mg + Isoniazid 30 mg where it is mentioned in the tender document. |
| 15. | All the tenderers are required to supply the products with printed Text "NACO SUPPLIES - NOT FOR SALE" in red colour on the strips, blisters, vials, ampoules & bottles and also on the external packings. | 14.7: Supply/De livery Conditions | In the technical specifications (Annexure 1 A), it is mentioned as NTEP Central Government Supply NOT FOR SALE. Also, the logo of NTEP is mentioned. Kindly clarify if we should additionally include the printed text " NACO supplies - NOT For SALE in red colour on the strips, and also on the external packings | M/s Lupin Ltd. | Amended as: - All the tenderers are required to supply the products with printed Text " NTEP SUPPLIES - NOT FOR SALE" in red colour on the strips, blisters, vials, ampoules & bottles and also on the external packings. |
| 16. | 6.2 d Technical Bid- Packet 1: The signature of authorized signatory should be duly attested. | | Kindly confirm if attestation by authorized company official is acceptable | M/s Lupin Ltd. | No changes. |
| 17. | Inspection Methodology (PDI/Non PDI): - Non-PDI (Inspection at Delivery Stages) | Annexure - I | | | Amended as: - Inspection Methodology (PDI/Non PDI): - Tranche I: - PDI (Pre- delivery Inspection) |

| | | | Rest Tranche 2 & 3: - Non-PDI (Inspection |
|-----|---|--------------------------------|---|
| | | | at Delivery Stages) |
| 18. | Manufacturing and Market Standing Certificate / Market Standing Certificate issued by the Licensing Authority as a | 6.2 (f) | Amended as: - Deleted. |
| | manufacturer for each item quoted for the last 2 years i.e. 2020-21 & 2021-22 OR 2021- 22 & 2022-23 for compliance of tender clause no. 4 (d). | | |
| 19. | For all regulated products, the bidder should have at least two | 4 (d) | Amended as: - |
| | years i.e. 2020- 21 and 2021-22 OR 2021-22 and 2022-23 of manufacturing and marketing experience of the particular items as a manufacturer for each | | Deleted. |
| | regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCG (I) in less than two years | | |
| | ago. A permission from DCG (I) shall be required for all new regulated products to this effect. | | |
| | Only for the drugs introduced in Indian Pharmacopoeia in the recent past last 2yrs), Market standing certificate for previously approved Pharmacopoeia or Inhouse Standards (Export/ Domestic) shall be accepted, as the case may be. | | |
| | For the recently introduced drugs in the county (introduced in the last two years), the requirement for Market standing certificate shall be waived off. | | |
| 20. | Annexure-IV should be signed by Statutory Auditor | Annexure- IV | Amended as: - |
| | | | Annexure-IV should be signed by Statutory Auditor/ Practicing Chartered Accountant |
| 21. | Storage: Store protected from light and moisture at room | Annexure- IA, | Amended as: - |
| | temperature. | Technical Specificatio n | Storage: Store protected from light and moisture at room |
| | | B. Storage | temperature. (25°C |

| | & Shelf-life | (77deg F); excursions permitted 15-30 °C (59-86 deg F) |
|-----|--------------|--|
| 22. | Annexure- | Amended as: - |
| | IA, | A strip consisting of |
| | Technical | individual blisters of |
| | Specificatio | the drug duly identified |
| | n | should be packed in an |
| | A & K | Aluminium- PVC |
| | Packaging | blister pack/Alu-Alu |
| | | strip pack. |

Note: - Above changes will be part of the tender document.

(Anjana) GM (Procurement)